Following an over 12% decline in the previous session in reaction to updates at the company’s R&D Day event, Moderna ...

Moderna MRNA announced a strategic overhaul and new financial guidance at its R&D day on Sept. 12, and we’ve lowered our fair value estimate to $141 per share from $227. We’ve repeatedly ...

Moderna announced a strategic overhaul and new financial guidance at its R&D day on Sept. 12, and we’ve lowered our fair value estimate to $141 per share from $227. We’ve repeatedly pointed to ...

Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID ...

The R&D Day event follows Imunon’s announcement of top-line data from its randomized Phase II Ovation 2 Study. These data suggest an 11.1 month increase in median OS in the intent-to-treat ...

CAMBRIDGE, MA / ACCESSWIRE / August 22, 2024 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event - R&D Day and Business Updates at 9:00 a.m. ET on Thursday ...

By investing heavily on EV R&D, India can further localise production to create more jobs, tap export markets to gain global ...

Following an over 12% decline in the previous session in reaction to updates at the company’s R&D Day event, Moderna (NASDAQ:MRNA) shares continued to tumble in the pre-market on Friday as J.P ...

today announced program and financial updates demonstrating progress and strategic prioritization of its mRNA pipeline at its annual R&D Day event. The updates include data readouts in the Company ...